Neomycin and Polymyxin B Sulfates and Hydrocortisone NEOMYCIN SULFATE POLYMYXIN B SULFATE AND HYDROCORTISONE BAUSCH & LOMB INCORPORATED FDA Approved Neomycin and polymyxin B sulfates and hydrocortisone otic suspension, USP is a sterile antibacterial and anti-inflammatory suspension for otic use. Each mL contains: Actives: neomycin sulfate equivalent to 3.5 mg neomycin base, polymyxin B sulfate equivalent to 10,000 polymyxin B units, and hydrocortisone 10 mg (1%); Inactives: cetyl alcohol (0.9%), polysorbate 80, propylene glycol, purified water. Sulfuric acid may be added to adjust pH (3.0 - 7.0). Preservative: thimerosal 0.01%. Neomycin sulfate is the sulfate salt of neomycin B and C, which are produced by the growth of Streptomyces fradiae Waksman (Fam. Streptomycetaceae). It has a potency equivalent of not less than 600 mcg of neomycin standard per mg, calculated on an anhydrous basis. The structural formulae are: Polymyxin B sulfate is the sulfate salt of polymyxin B 1 and B 2 , which are produced by the growth of Bacillus polymyxa (Prazmowski) Migula (Fam. Bacillaceae). It has a potency of not less than 6,000 polymyxin B units per mg, calculated on an anhydrous basis. The structural formulae are: Hydrocortisone, 11β, 17, 21-trihydroxypregn-4-ene-3, 20-dione, is an anti-inflammatory hormone. Its structural formula is: ChemS ChemSt ChemStr
FunFoxMeds bottle
Substance Hydrocortisone
Route
AURICULAR (OTIC)
Applications
ANDA064065
Package NDC

Drug Facts

Composition & Profile

Strengths
10 ml
Quantities
10 ml
Treats Conditions
Indications And Usage For The Treatment Of Superficial Bacterial Infections Of The External Auditory Canal Caused By Organisms Susceptible To The Action Of The Antibiotics And For The Treatment Of Infections Of Mastoidectomy And Fenestration Cavities Caused By Organisms Susceptible To The Antibiotics

Identifiers & Packaging

Container Type BOTTLE
All Product Codes
UNII
WI4X0X7BPJ 057Y626693 19371312D4
Packaging

HOW SUPPLIED Neomycin and polymyxin B sulfates and hydrocortisone otic suspension, USP is supplied in a white plastic dropper bottle in the following size: 10 mL bottle - NDC 24208-635-62 Storage: Store at 15°C to 25°C (59°F to 77°F). FOR USE IN EARS ONLY. KEEP OUT OF REACH OF CHILDREN. Distributed by: Bausch & Lomb Americas Inc. Bridgewater, NJ 08807 USA Manufactured by: Bausch & Lomb Incorporated Tampa, FL 33637 USA © 2025 Bausch & Lomb Incorporated or its affiliates Revised: March 2025 9115707 (Folded) 9115607 (Flat) DoNotUse; PACKAGE/LABEL PRINCIPAL DISPLAY PANEL NDC 24208-635-62 Neomycin and Polymyxin B Sulfates and Hydrocortisone Otic Suspension USP (Sterile) [EAR IMAGE ] FOR USE IN EARS ONLY Rx only 10 mL Bausch + Lomb 9537001 Carton

Package Descriptions
  • HOW SUPPLIED Neomycin and polymyxin B sulfates and hydrocortisone otic suspension, USP is supplied in a white plastic dropper bottle in the following size: 10 mL bottle - NDC 24208-635-62 Storage: Store at 15°C to 25°C (59°F to 77°F). FOR USE IN EARS ONLY. KEEP OUT OF REACH OF CHILDREN. Distributed by: Bausch & Lomb Americas Inc. Bridgewater, NJ 08807 USA Manufactured by: Bausch & Lomb Incorporated Tampa, FL 33637 USA © 2025 Bausch & Lomb Incorporated or its affiliates Revised: March 2025 9115707 (Folded) 9115607 (Flat) DoNotUse
  • PACKAGE/LABEL PRINCIPAL DISPLAY PANEL NDC 24208-635-62 Neomycin and Polymyxin B Sulfates and Hydrocortisone Otic Suspension USP (Sterile) [EAR IMAGE ] FOR USE IN EARS ONLY Rx only 10 mL Bausch + Lomb 9537001 Carton

Overview

Neomycin and polymyxin B sulfates and hydrocortisone otic suspension, USP is a sterile antibacterial and anti-inflammatory suspension for otic use. Each mL contains: Actives: neomycin sulfate equivalent to 3.5 mg neomycin base, polymyxin B sulfate equivalent to 10,000 polymyxin B units, and hydrocortisone 10 mg (1%); Inactives: cetyl alcohol (0.9%), polysorbate 80, propylene glycol, purified water. Sulfuric acid may be added to adjust pH (3.0 - 7.0). Preservative: thimerosal 0.01%. Neomycin sulfate is the sulfate salt of neomycin B and C, which are produced by the growth of Streptomyces fradiae Waksman (Fam. Streptomycetaceae). It has a potency equivalent of not less than 600 mcg of neomycin standard per mg, calculated on an anhydrous basis. The structural formulae are: Polymyxin B sulfate is the sulfate salt of polymyxin B 1 and B 2 , which are produced by the growth of Bacillus polymyxa (Prazmowski) Migula (Fam. Bacillaceae). It has a potency of not less than 6,000 polymyxin B units per mg, calculated on an anhydrous basis. The structural formulae are: Hydrocortisone, 11β, 17, 21-trihydroxypregn-4-ene-3, 20-dione, is an anti-inflammatory hormone. Its structural formula is: ChemS ChemSt ChemStr

Indications & Usage

For the treatment of superficial bacterial infections of the external auditory canal caused by organisms susceptible to the action of the antibiotics, and for the treatment of infections of mastoidectomy and fenestration cavities caused by organisms susceptible to the antibiotics.

Dosage & Administration

Therapy with this product should be limited to 10 consecutive days. The external auditory canal should be thoroughly cleansed and dried with a sterile cotton applicator. For adults, 4 drops of the suspension should be instilled into the affected ear 3 to 4 times daily. For children, 3 drops are suggested because of the smaller capacity of the ear canal. The patient should lie with the affected ear upward and then the drops should be instilled. This position should be maintained for 5 minutes to facilitate penetration of the drops into the ear canal. Repeat, if necessary, for the opposite ear. If preferred, a cotton wick may be inserted into the canal and then the cotton may be saturated with the suspension. This wick should be kept moist by adding further suspension every 4 hours. The wick should be replaced at least once every 24 hours. SHAKE WELL BEFORE USING.

Warnings & Precautions
WARNINGS Neomycin can induce permanent sensorineural hearing loss due to cochlear damage, mainly destruction of hair cells in the organ of Corti. The risk is greater with prolonged use. Therapy should be limited to 10 consecutive days (see PRECAUTIONS-General ). Patients being treated with eardrops containing neomycin should be under close clinical observation. Neomycin and polymyxin B sulfates and hydrocortisone otic suspension should not be used in any patient with a perforated tympanic membrane. Discontinue promptly if sensitization or irritation occurs. Neomycin sulfate may cause cutaneous sensitization. A precise incidence of hypersensitivity reactions (primarily skin rash) due to topical neomycin is not known. When using neomycin-containing products to control secondary infection in the chronic dermatoses, such as chronic otitis externa or stasis dermatitis, it should be borne in mind that the skin in these conditions is more liable than is normal skin to become sensitized to many substances, including neomycin. The manifestation of sensitization to neomycin is usually a low-grade reddening with swelling, dry scaling, and itching; it may be manifest simply as a failure to heal. Periodic examination for such signs is advisable, and the patient should be told to discontinue the product if they are observed. These symptoms regress quickly on withdrawing the medication. Neomycin containing applications should be avoided for the patient thereafter.
Contraindications

This product is contraindicated in those individuals who have shown hypersensitivity to any of its components, and in herpes simplex, vaccinia, and varicella infections.

Adverse Reactions

Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see WARNINGS ). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria. Stinging and burning have been reported rarely when this drug has gained access to the middle ear. To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.


Similar Drugs

Related medications based on brand, generic name, substance, active ingredients.

View all similar drugs →